PRTN3 and rheumatoid arthritis: Our findings motivate future research into the immunological differences between ACPA+ RA and ACPA− RA, hopefully providing new insights into the need for different treatment approaches, and into potentially new autoantibody biomarker tests and therapeutic leads.